Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

17.91 -0.15 (-0.83%)

Official Closing Price Updated: 7:00 PM EDT, Mar 27, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	2,311,160
Open	18.00
Bid (Size)	15.01 (400)
Ask (Size)	17.92 (300)
Prev. Close	18.06
Today's Range	17.87 - 18.19
52wk Range	12.99 - 18.82
Shares Outstanding	1,557,765,596
Dividend Yield	3.79%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care

March 28, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH

March 26, 2026

On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI)...

Via Finterra

Performance

YTD	+14.7%	+14.7%
1 Month	-3.3%	-3.3%
3 Month	+13.6%	+13.6%
6 Month	+22.5%	+22.5%
1 Year	+19.0%	+19.0%

More News

The Great Resurgence: A Deep Dive into Grifols S.A. (GRFS) in 2026

March 25, 2026

Via Finterra

The Great Unbundling: How AI’s Insatiable Hunger is Driving a Corporate Divestiture Gold Rush

March 18, 2026

Via MarketMinute

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

March 02, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity

February 24, 2026

Via FinancialNewsMedia

Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

February 19, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market

February 10, 2026

Via FinancialNewsMedia

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1

February 10, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda (TAK) Q2 2025 Earnings Call Transcript ↗

February 05, 2026

Via The Motley Fool

Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead

January 29, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1

January 22, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

January 05, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance

January 02, 2026

Via MarketMinute

Regencell Bioscience (RGC) Stumbles into 2026: 8% Year-End Slide Sparks Technical Caution

January 01, 2026

Via MarketMinute

The Next Big Buyout? Abivax Emerges as a Premier M&A Contender for 2026 Amidst Biotech Consolidation Wave

December 23, 2025

Via MarketMinute

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

December 18, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

December 06, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Pharmaceuticals’ Genetic Disease Therapy Under FDA Probe After Pediatric Patient Dies ↗

November 21, 2025

Via Stocktwits

Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile ↗

November 11, 2025

Via Benzinga

AI’s Next Frontier: Key Stocks to Watch Amidst Market Shifts and Technological Leaps

November 10, 2025

Via TokenRing AI

Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy

November 07, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

November 06, 2025

Via MarketMinute

New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization

November 03, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges ↗

October 30, 2025

Via Benzinga

Frequently Asked Questions

Is Takeda Pharmaceutical Company Limited American Depositary Shares (each publicly traded?

Yes, Takeda Pharmaceutical Company Limited American Depositary Shares (each is publicly traded.

What exchange does Takeda Pharmaceutical Company Limited American Depositary Shares (each trade on?

Takeda Pharmaceutical Company Limited American Depositary Shares (each trades on the New York Stock Exchange

What is the ticker symbol for Takeda Pharmaceutical Company Limited American Depositary Shares (each?

The ticker symbol for Takeda Pharmaceutical Company Limited American Depositary Shares (each is TAK on the New York Stock Exchange

What is the current price of Takeda Pharmaceutical Company Limited American Depositary Shares (each?

The current price of Takeda Pharmaceutical Company Limited American Depositary Shares (each is 17.91

When was Takeda Pharmaceutical Company Limited American Depositary Shares (each last traded?

The last trade of Takeda Pharmaceutical Company Limited American Depositary Shares (each was at 03/27/26 07:00 PM ET

What is the market capitalization of Takeda Pharmaceutical Company Limited American Depositary Shares (each?

The market capitalization of Takeda Pharmaceutical Company Limited American Depositary Shares (each is 27.90B

How many shares of Takeda Pharmaceutical Company Limited American Depositary Shares (each are outstanding?

Takeda Pharmaceutical Company Limited American Depositary Shares (each has 28B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.